Proalgen Biotech Profile
Key Indicators
- Authorised Capital ₹ 15.00 Cr
- Paid Up Capital ₹ 11.99 Cr
- Company Age 27 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.47 Cr
- Satisfied Charges ₹ 18.69 Cr
- Revenue Growth -24.74%
- Profit Growth -113.59%
- Ebitda 74.11%
- Net Worth -7.76%
- Total Assets -0.75%
About Proalgen Biotech
Proalgen Biotech Limited (PBL) is a Public Limited Indian Non-Government Company incorporated in India on 03 March 1997 and has a history of 27 years and 11 months. Its registered office is in Chennai, Tamil Nadu, India.
The Corporate was formerly known as Acl Chemicals Ltd. The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 15.00 Cr and a paid-up capital of Rs 11.99 Cr.
The company currently has active open charges totaling ₹6.47 Cr. The company has closed loans amounting to ₹18.69 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Proalgen Biotech Limited India is Ponnurangam Selvakumar as CFO. Kalyanasundaram Krishnan, Nidamangala Balamukundan, Nidamangala Venkatesh, and One other member serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24117TN1997PLC037629
- Company No.
037629
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
03 Mar 1997
- Date of AGM
25 Oct 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
What products or services does Proalgen Biotech Limited offer?
Proalgen Biotech Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Vitamin Powder API.
Who are the key members and board of directors at Proalgen Biotech?
Executive Team (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Nidamangala Balamukundan ![]() | Managing Director | 01-Jan-1998 | Current |
Ponnurangam Selvakumar ![]() | CFO | 01-Jun-2019 | Current |
Board Members (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Kalyanasundaram Krishnan ![]() | Director | 29-Nov-2021 | Current |
Nidamangala Venkatesh ![]() | Director | 10-Jul-1999 | Current |
Ananthanarayanan Manjunath ![]() | Director | 29-Feb-2020 | Current |
Financial Performance of Proalgen Biotech.
Proalgen Biotech Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 24.74% decrease. The company also saw a substantial fall in profitability, with a 113.59% decrease in profit. The company's net worth dipped by a decrease of 7.76%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Proalgen Biotech?
In 2022, Proalgen Biotech had a promoter holding of 71.56% and a public holding of 28.43%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹6.47 Cr
₹18.69 Cr
Charges Breakdown by Lending Institutions
- Others : 4.31 Cr
- State Bank Of India : 2.16 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
13 Mar 2009 | Others | ₹4.31 Cr | Open |
08 Apr 2005 | State Bank Of India | ₹2.16 Cr | Open |
14 Apr 2005 | Icici Limited | ₹7.00 Cr | Satisfied |
14 Apr 2005 | Icici Bank Ltd | ₹7.00 Cr | Satisfied |
30 Jan 2002 | The Vyasya Bank Ltd. | ₹3.79 Cr | Satisfied |
How Many Employees Work at Proalgen Biotech?
Unlock and access historical data on people associated with Proalgen Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Proalgen Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Proalgen Biotech's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.